Fig. 5: Synergistic antitumor effect of combined sorafenib and LZX-2-73 treatment in a tumor xenograft mouse model. | Cell Death & Disease

Fig. 5: Synergistic antitumor effect of combined sorafenib and LZX-2-73 treatment in a tumor xenograft mouse model.

From: Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models

Fig. 5

Female Crl:NU(Ico)-Foxn1nu mice implanted with pancreatic cancer MIAPaCa-2 cell lines xenografts and treated daily with sorafenib (25 mg/kg), LZX-2-73 (10 mg/kg), or a combination of both drugs (25 mg/kg + 10 mg/kg) via intraperitoneal injection. A Tumor volume was measured twice per week. Data are shown as mean ± SEM. *p < 0.05, ****p < 0.0001 (1-way ANOVA, Dunnett’s test, compared to combinatory treatment). B Representative images of tissue sections following Ki-67 IHC staining and TUNEL assay from mice treated with sorafenib (25 mg/kg), LZX-2-73 (10 mg/kg), or their combination. Scale bar: 100 μm. C The levels of malondialdehyde (MDA) and (D) 4-Hydroxynonenal, and (E) the activity of glutathione peroxidase (GPx) were assessed in MIAPaCa-2 xenografted tumors following a 4-week treatment with sorafenib, LZX-2-73, or a combination of both. Statistical significance is indicated as follows: ns: not significant, ***p < 0.001 (1-way ANOVA, Dunnett’s test, compared to combinatory treatment). Scale bar: 100 μm.

Back to article page